Free Trial
NASDAQ:PSTX

Poseida Therapeutics (PSTX) Stock Price, News & Analysis

$3.37
-0.24 (-6.65%)
(As of 09/20/2024 ET)

About Poseida Therapeutics Stock (NASDAQ:PSTX)

Key Stats

Today's Range
$3.31
$3.61
50-Day Range
$2.70
$4.04
52-Week Range
$1.83
$4.27
Volume
954,336 shs
Average Volume
568,744 shs
Market Capitalization
$327.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.67
Consensus Rating
Buy

Company Overview

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Poseida Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 76th Percentile

Poseida Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 268th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Poseida Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Poseida Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Poseida Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.57) to ($1.97) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Poseida Therapeutics is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Poseida Therapeutics is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Poseida Therapeutics has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Poseida Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.02% of the outstanding shares of Poseida Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Poseida Therapeutics has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Poseida Therapeutics has recently increased by 6.27%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Poseida Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Poseida Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.02% of the outstanding shares of Poseida Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Poseida Therapeutics has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Poseida Therapeutics has recently increased by 6.27%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Poseida Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Poseida Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    5 people have searched for PSTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Poseida Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.90% of the stock of Poseida Therapeutics is held by insiders.

  • Percentage Held by Institutions

    46.87% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Poseida Therapeutics' insider trading history.
Receive PSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTX Stock News Headlines

Forget Trump and Kamala
Forget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.
See More Headlines

PSTX Stock Analysis - Frequently Asked Questions

Poseida Therapeutics' stock was trading at $3.36 at the beginning of the year. Since then, PSTX shares have increased by 3.3% and is now trading at $3.47.
View the best growth stocks for 2024 here
.

Poseida Therapeutics, Inc. (NASDAQ:PSTX) posted its quarterly earnings results on Monday, August, 5th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.11. The firm had revenue of $25.97 million for the quarter, compared to the consensus estimate of $13.75 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 121.01% and a negative net margin of 127.48%.

Poseida Therapeutics (PSTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair acted as the underwriters for the IPO.

Top institutional investors of Poseida Therapeutics include Blair William & Co. IL (1.14%), Renaissance Technologies LLC (0.88%), Dimensional Fund Advisors LP (0.62%) and Acadian Asset Management LLC (0.41%). Insiders that own company stock include Life Sciences Holdings L Malin, Eric Ostertag and Kerry D Ingalls.
View institutional ownership trends
.

Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW) and OPKO Health (OPK).

Company Calendar

Last Earnings
8/05/2024
Today
9/20/2024
Next Earnings (Estimated)
11/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PSTX
Fax
N/A
Employees
260
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.67
High Stock Price Target
$20.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+306.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-123,430,000.00
Net Margins
-127.48%
Pretax Margin
-127.36%

Debt

Sales & Book Value

Annual Sales
$88.46 million
Book Value
$1.08 per share

Miscellaneous

Free Float
94,146,000
Market Cap
$350.02 million
Optionable
Optionable
Beta
0.51
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:PSTX) was last updated on 9/20/2024 by MarketBeat.com Staff
From Our Partners